Integrin interaction inhibitors for the treatment of cancer
US-10059740-B2 · Aug 28, 2018 · US
US10197575B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10197575-B2 |
| Application number | US-201515300451-A |
| Country | US |
| Kind code | B2 |
| Filing date | Mar 31, 2015 |
| Priority date | Mar 31, 2014 |
| Publication date | Feb 5, 2019 |
| Grant date | Feb 5, 2019 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
The current invention pertains to stabilized peptoids or peptoid-peptide hybrids. The peptoids or peptoid-peptide hybrids are stabilized by side chain-side to side chain linkages and/or backbone cyclization. The current invention also provides a positional library scanning method for identification of peptoids or peptoid-peptide hybrids having a desired biological activity.
Opening claim text (preview).
We claim: 1. A stapled peptoid comprising a plurality of N-substituted glycines, wherein at least two of the N-substituted glycines are linked to each other by an intramolecular cross-link between the N-substitutions, and wherein the length and geometry of the cross-link pre-organizes the peptoid into a desired conformation. 2. A stapled peptoid-peptide hybrid comprising a plurality of amino acids and a plurality of N-substituted glycines, wherein at least two residues from the plurality of amino acids and the plurality of N-substituted glycines are linked to each other by an intramolecular cross-link, and wherein the length and geometry of the intramolecular cross-link provides stability to the peptoid-peptide hybrid. 3. The stapled peptoid-peptide hybrid of claim 2 , wherein two N-substituted glycine residues or two amino acid residues are linked to each other by the intramolecular cross-link. 4. The stapled peptoid-peptide hybrid of claim 2 , wherein an N-substituted glycine residue is linked to an amino acid residue by the intramolecular cross-link. 5. The stapled peptoid-peptide hybrid of claim 2 , wherein the peptoid-peptide hybrid is a cyclic peptoid-peptide hybrid, the cyclic peptoid-peptide hybrid comprising a plurality of alternating peptoid-peptide sequences, wherein the peptoid-peptide sequences form at least two antiparallel beta-strands. 6. The stapled peptoid-peptide hybrid of claim 2 , further comprising substitutions on the amino acid side chains or the N-substitutions on glycines, wherein the substitutions further stabilize the peptoid-peptide hybrids. 7. The stapled peptoid-peptide hybrid of claim 2 , wherein one or more of the substitutions are selected from the groups listed in Table 1 or shown in FIG. 9 , and wherein the substitutions may be the same or different. 8. The stapled peptoid-peptide hybrid of claim 2 , wherein the peptoid-peptide hybrid is selected from formula I, formula II, formula III, formula IV, formula V, formula VI, formula VII, formula VIII, formula IX, formula X, formula XI, or formula XII. 9. The stapled peptoid-peptide hybrid of claim 8 , wherein one or more of the R groups are selected from the groups listed in Table 1 or shown in FIG. 9 . 10. The stapled peptoid-peptide hybrid of claim 2 , wherein the peptoid-peptide hybrid is that of FIG. 1A , optionally including the attached linker, or optionally including the attached linker and resin. 11. The stapled peptoid-peptide hybrid of claim 10 , wherein one or more of the R groups (R 1 , R 2 , R 3 , or R 4 ) are selected from the groups listed in Table 1 or shown in FIG. 9 . 12. The stapled peptoid-peptide hybrid of claim 2 , wherein the peptoid-peptide hybrid is that of FIG. 1B or 1C . 13. The stapled peptoid-peptide hybrid of claim 2 , wherein the peptoid-peptide hybrid is that of FIG. 3 , FIG. 4 , FIG. 5 , or FIG. 6 . 14. The stapled peptoid-peptide hybrid of claim 13 , wherein one or more of the variable side chains are selected from the groups listed in Table 1 or shown in FIG. 9 . 15. The stapled peptoid-peptide hybrid of claim 2 , wherein the peptoid-peptide hybrid is that of FIG. 7 or FIG. 8 , optionally including the attached resin. 16. A positional library of the peptoid-peptide hybrid of claim 2 .
Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof · CPC title
Cyclic peptides containing only normal peptide links · CPC title
Methods of identifying protein-protein interactions in protein mixtures · CPC title
involving proteins, peptides or amino acids {(involving lipoproteins G01N33/92)} · CPC title
Proteomic analysis of subsets of protein mixtures with reduced complexity, e.g. membrane proteins, phosphoproteins, organelle proteins · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.